I completed all my formal studies at the University of Valencia, but I have always been interested in experiencing science beyond my home institution. As an undergraduate, I participated in an Erasmus program at Nottingham Trent University, and during my PhD, I did a three-month internship at the Cologne Cluster of Excellence CECAD at the University of Cologne. Working alongside researchers from different countries has shown me how the diversity of perspectives enriches the scientific process and fosters innovative thinking.

Leyla Kragten-Tabatabaie has a background in Medical Biology and received her PhD in Metabolic diseases in children at the Wilhelmina Children’s Hospital, University Medical Center in Utrecht, The Netherlands. Leyla Kragten-Tabatabaie has been involved from the beginning with the inception, shaping and managing of ReSViNET and has a central role in all ReSViNET activities including communications with ReSViNET (scientific) board, involvement in clinical trials and related educational activities and organizing scientific conferences and masterclasses. She has set up and is the former project leader for the RSV GOLD study, is involved in the ReSViNET activities for the RESCEU study and plays a crucial role in all ReSViNET RSV studies regarding patient advisory board activities, peer-to-peer education for the site study team and overall communication lines between the sponsor, project manager and Principal investigator ensuring clinical trials are smoothly and efficiently rolled-out in the network.  

Lin H Chen currently works at the Travel Medicine Center, Mount Auburn Hospital. Lin does research in Travel Medicine.

Prof Wang is a Professor in the Programme in Emerging Infectious Diseases at Duke-NUS Medical School and the inaugural Executive Director of the Programme for Research in Epidemic Preparedness and Response (PREPARE), Singapore. He is one of the world’s leading experts in zoonotic diseases, bat immunology and pathogen discovery.



His early research was at the Monash Centre for Molecular Biology and Medicine. In 1990, he joined the Commonwealth Scientific and Industrial Research Organization (CSIRO), Australian Animal Health Laboratory (AAHL) where he played a leading role in identifying bats as the natural host of the Severe Acute Respiratory Syndrome (SARS) virus. His research then extended from bat-borne viruses to better understand virus-bat interaction and how bats co-exist with a large number of viruses without developing clinical diseases. His recent research contributions include developing antibody based serological tests to detect the SARS-CoV-2 virus, responsible for the COVID-19 outbreak, and the early and successful culture of the virus from an infected patents sample. His team is currently focusing on research into the origin of SARS-CoV-2, developing assays which can better assess vaccine efficacy in the context of a potential immunity passport strategy and novel vaccination strategy to broaden protective immunity against future variants and emerging SARS-related coronaviruses.



Prof Wang is a member of multiple World Health Organization committees on COVID-19. His work has been recognised internationally through various international awards, numerous invited speeches at major international conferences and more than 500 scientific papers including many top scientific publications in Science, Nature, New England Journal of Medicine, Lancet, along with nice patents and many invited book chapters. He holds a number of honorary positions and memberships and has received numerous awards. Prof Wang was elected to the Australian Academy of Technological Sciences and Engineering in 2010 and the American Academy of Microbiology in 2021 in recognition of his expertise in new and emerging diseases. He received the Singapore’s President Science Award in 2021. He is also active internationally by serving on various editorial boards for publication in the areas of virology, microbiology and infectious diseases. He is currently the Editor-in-Chief of the Virology Journal.

Nationality:

Austrian

Position:

Assistant Professor, Department of Viroscience, Erasmus MC, The Netherlands

Research Fields: 

Neuropathogenesis of respiratory viruses, Virus replication, stem cells, organoids, Picornaviruses, Enteroviruses, Influenza A viruses, SARS-CoV-2, Monkeypox virus

Short description:

Lisa is Assistant Professor at the Department of Viroscience at the Erasmus MC. Lisa obtained her PhD in February 2021 in the group of Frank van Kuppeveld at Utrecht University, Netherlands within the European Marie Curie Training Network “Antivirals” where she characterized FDA- approved drugs that inhibit enterovirus replication and developed novel broad-spectrum antientero/rhinovirus compounds. In March 2020, Lisa joined the team of Debby van Riel as a post-doc at the Viroscience Department of Erasmus MC in Rotterdam, Netherlands, where she studied how respiratory viruses spread to extra-respiratory tissues. Her independent research line aims to unravel the complex interplay between viruses and the central nervous system (CNS), focusing on how viruses from various families differentially affect cells of the CNS, trigger neuroinflammation, and disrupt the CNS homeostasis. Her investigation centres on three interconnected questions: (1) how viral infections modulate cellular, immunological, and metabolic responses within neural cells and tissue; (2) viral dissemination pathways within the CNS; and (3) identification of host factors facilitating neuropathogenesis. She employs human induced pluripotent stem cell (hPSC)-derived neural cultures, brain organoids, and organotypic brain slices as experimental models. This platform enabled her to advance our understanding of neuropathological mechanisms in emerging viruses including SARS-CoV-2, MPOX virus, highly pathogenic avian influenza virus H5N1, and enteroviruses. 

Lotte Steuten is a health economist by training and primarily interested in health technology assessment and decision analytic modelling of health innovations. 

Alongside her position at OHE, Lotte is a Visiting Honorary Professor at City University of London, a member of the ISPOR Board of Directors and associate editor at Value in Health. She has published >100 peer-reviewed papers. 

Lotte’s current research interests include applied health economics, health policy and market access. She specializes in quantitative methods for estimating and comparing the expected health and economic benefits of new interventions across their lifecycle, and novel approaches to efficiently building the evidence for these.

Dr Louise Rowntree is an early-mid career scientist with extensive expertise in viral immunology in vulnerable populations. Louise completed her PhD in 2016 at Monash University investigating human cross-reactive CD8+ T-cells in viral infections.

She joined Professor Tony Purcell's Laboratory (Monash) between 2016-2018 to further explore T-cell cross-reactivity between viral and self-antigens and identify allopeptides. Louise joined Prof Katherine Kedzierska’s Laboratory (UoM) in 2019, where her work focuses on dissecting anti-viral responses in high-risk groups, including First Nations peoples, patients with co-morbidities, children and pregnant women, with an emphasis on T-cell epitope identification and T-cell responses associated with severe disease.



Louise has worked in viral T-cell immunity since 2011, most recently on influenza and SARS-CoV-2. She has published a number of peer-reviewed research articles, exemplified by a world-first report of a SARS-CoV-2 CD8+ T-cell specificity early in the pandemic (PNAS-2020) and publications detailing the establishment of SARS-CoV-2-specific T-cells following COVID-19 infection in adults (Immunity-2021) and children (Immunity-2022). She is the recipient of an Australian Postgraduate Award (2012), Rutherford Fellowship (2018), Best Oral European Federation for Immunogenetics (2015) and Keystone Symposia Scholarship (2022). Her emerging international profile is recognized by internationally invited talks and selected inter/national abstract presentations with travel grants and speaker prizes.

Lucy Mosscrop is a final year PhD student in the group of Professor John Tregoning at Imperial College London, co-supervised by Professor Maria Zambon (UK Health Security Agency/UKHSA) and Professor Peter Openshaw (NHLI, Imperial College London). Her work is supported by the Health Protection Research Unit in Respiratory Infections in collaboration with UKHSA. 

Lucy’s research focus is on respiratory syncytial virus (RSV) specifically the fusion or F protein and how it has evolved and may continue to evolve as new interventions are implemented. As part of this work, she has collaborated extensively with UKHSA to help set up an improved RSV whole-genome sequencing assay (WGS) which has since been used to sequence over 1000 RSV-positive clinical samples from the UK (data available on GISAID). She is using this surveillance data to screen for potential RSV monoclonal antibody resistance mutations and test the biological consequences of these changes via reverse genetics systems. Ultimately hoping to establish a pipeline of surveillance, phenotyping and continuous monitoring.

Dr Lwazi Manzi is a medical doctor specialised in Emergency Medicine. She obtained her degrees from the University Of Cape Town.



She has a strong history of executive and industry leadership. Her 15 year career spans emergency medicine, music, television and film production and media relations. In 2019 she was appointed Media Liaison Officer and the Spokesperson for the Minister of Health in South Africa during a pivotal period in the history of South Africa’s health policy, namely the introduction of the National Health Insurance bill and through the management of the COVID-19 pandemic. Dr Manzi has been appointed as Head of the newly created Secretariat of the African Union Commission on COVID-19. The Commission will work within the established African Continental Strategy structures and the Africa CDC on the control of the COVID pandemic.

Director Research Institute SHARE; advisor to WHO, EU & Health Council; scientific advisory boards for / scientific advice to various pharmaceutical industries and consultancies, inclusive some RuG spin-offs; various editorships, inclusive PLoS One, Expert Reviews of Pharmacoeconomics & Outcomes Research, Expert Review of Clinical Pharmacology and BMC Health Services Research; assessor for Kenniscentrum (KCE; Belgium); member JCVI; external teacher (for example, Bielefeld, Germany); assessor All Wales Medicines Strategy Group (Grwp Strategaeth Meddyginiaethau Cymru Gyfan), shareholder Health-Ecore; owner Pharmacoeconomics Advice Groningen

Mamadou Malado Jallow graduated from the Senegalese High School in Banjul (The Gambia) in 2012. Subsequently, I was admitted at the University Cheikh Anta Diop de Dakar (Senegal) with a cooperation scholarship to pursue a degree in Biology. In 2015, I was selected to pursue a Master degree in Parasitology after achieving my BSc with a distinction. As part of my thesis, I joined the Pasteur Institute in Dakar in July 2017 and contributed in several research projects. My research interest is to investigate the epidemiology and the genetic characteristics of Influenza A viruses at the human/animal interface as well as the risk assessment of Avian Influenza Virus (AIV) emergence and transmission to Human.

Marco Del Riccio is a Medical Doctor specialized in Public Health and Preventive Medicine at the University of Florence, where he currently serves as a Researcher and Assistant Professor. He is also a Guest Researcher at the Netherlands Institute for Health Services Research (Nivel), where he initiated his PhD journey in collaboration with Dr. John Paget. As a PhD candidate, his research explores the impact of the COVID-19 pandemic on the epidemiology and burden of respiratory viruses, as well as preventive medicine strategies. He is completing his PhD at Radboud University Nijmegen under the supervision of Prof. Dr. Aura Timen. He is a member of the Scientific Secretariat of the Adult Immunization Board and other national and international initiatives, including the Global Influenza Initiative (GII) and the Steering Group on Influenza Vaccination. He is also part of the Board of the National Working Group on Communication for Public Health of the Italian Society of Hygiene, Preventive Medicine and Public Health. He is author of over 70 scientific publications in international indexed journals and his main research interests include the epidemiology, burden of disease, and prevention strategies for respiratory infections, as well as vaccine hesitancy and vaccine literacy.

Nationality: Dutch 

Position: Intensivist, Spaarne Gasthuis, Amsterdam, The Netherlands; and Senior Scientist, Erasmus MC, Rotterdam, The Netherlands

Research fields: Special interest in acute care and infectious diseases

ESWI member since 2016

Marco Goeijenbier completed his Ph.D. in virology, focusing on "Haemostasis and Virus Infection," at Erasmus University Rotterdam in 2015. He currently serves as a specialist in acute internal medicine and critical care at Spaarne Hospital in Haarlem, The Netherlands. His expertise spans various aspects of infectious diseases, particularly in critical care medicine and viral infections. In addition to his clinical work, Goeijenbier holds a research position at Erasmus MC in Rotterdam, where he mentors PhD students exploring critical care medicine and viral infections. His research interests focus on severe acute respiratory infection (SARI) pathogenesis, epidemiology, and their interaction with the coagulation system.

Some of Goeijenbier’s most published articles include:

1. Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism 
2.  Determinants of vaccination uptake in risk populations: A comprehensive literature review. 
3. Benefits of flu vaccination for persons with diabetes mellitus. 
4. Early Patient-Triggered Pressure Support Breathing in Mechanically Ventilated Patients with COVID-19 May Be Associated with Lower Rates of Acute Kidney Injury

Dr. Goeijenbier is ESWI’s lead member and Chair in the Influenza Diabetes Community (IDC). The IDC connects leading diabetes, patient, scientific, and professional organizations around the common aim of protecting persons living with diabetes from influenza and other viral respiratory diseases like COVID-19.

Starting January 2023, Dr. Goeijenbier has taken on the role of Chair of Medical Research and Education at Spaarne Hospital. Furthermore, since January 2024, Marco is the Editor in Chief for Nature Springer Tropical Diseases, Travel Medicine, and Vaccines.

Dr. Maria Van Kerkhove is the COVID-19 Technical Lead for the World Health Organization and the Head of Emerging Diseases and Zoonoses in WHO’s Health Emergencies Programme. She is an infectious disease epidemiologist.



Van Kerkhove’s research spans zoonotic emerging and re-emerging high threat pathogens such as avian influenza, MERS-CoV, SARS, SARS-CoV-2, Ebola, Marburg, plague and Zika. She is responsible for the health operations and technical aspects of the global COVID-19 response as well as developing strategies for the prevention, preparedness and control of epidemic and pandemic zoonotic pathogens. For more than 25 years, her research has focused on factors associated with transmission between animals and humans, the epidemiology of zoonotic pathogens, and ensuring that research directly informs public health policies for action.



Van Kerkhove completed her undergraduate degree at Cornell University, an MS Degree in epidemiology at Stanford University and a PhD in infectious disease epidemiology at the London School of Hygiene and Tropical Medicine. Prior to joining WHO in 2017, she was the Head of the Outbreak Investigation Task Force at Institut Pasteur’s Center for Global Health, in Paris, where she was responsible for establishing public health rapid response teams for infectious disease outbreaks. Her previous roles include a senior fellow at Imperial College London in the MRC Center for Outbreak Analysis and Modelling, and an epidemiologist at the Institut Pasteur in Cambodia.

I received my degree in Medicine and Surgery from the University of Palermo, Italy in 2020. Since 2021, I’ve been attending the Graduate School of Geriatrics and Gerontology from the same University. Before starting the Graduate School, I worked on the COVID-19 vaccination campaign as a vaccination doctor. My research is mainly focused on the most common diseases affecting older people, such as neurocognitive disorders. I’m the author of two articles published in international scientific journals.

Nationality: French

Position: research director at INRAe, France

Research fields: Animal respiratory viruses

Mariette Ducatez is research director at INRAe, in Interactions Hosts-pathogens (IHAP) research unit. She worked in Luxembourg and then in the United States before coming to Toulouse. She has been a researcher in virology since 2006 with a particular interest in influenza viruses with a human-animal interface, and more generally animal respiratory viruses. She works both on animal virus surveillance projects (mainly in Africa), projects aimed at understanding the pathogenesis and transmission of these pathogens, as well as on issues of prevention and control of viral diseases.

Dr Marios Koutsakos completed undergraduate and post-graduate studies at Imperial College in London. He subsequently undertook a PhD and post-doctoral training in the Department of Microbiology and Immunology, University of Melbourne, focusing on understanding protective immunity to influenza B viruses He is now a group leader at the Doherty Institute, working on dissecting the antigenic evolution of influenza viruses as well as the evolution of antibody-mediated immunity to influenza viruses in order to improve vaccine design.

Dr Mark Eccleston-Turner is a Senior Lecturer in Global Health Law. He specialises in infectious diseases and international law, particularly the law of international organizations, pathogen sharing and equitable access to vaccines in a pandemic.



Mark has provided advice to the UK Foreign and Commonwealth Office and Department for International Development, and is a member of UK Parliament COVID-19 Outbreak Expert Database. He has appeared as a witness before the Foreign Affairs Select Committee, and has provided evidence to the Joint Committee on the National Security.



He has held visiting positions at the Brocher Foundation, in Geneva, Georgetown University School of Law, and as an Emerging Leader in Biosecurity Fellow at the Johns Hopkins Centre for Health Security. He has also worked as a Consultant to the World Health Organisation.



Mark regularly appears in national and international media to discuss international law and infectious diseases. His interviews have appeared on: Al Jazeera TV, Euronews, BBC News, Sky News, New York Times, Washington Post, South China Morning Post, and The Times. In 2021, in recognition of his work on equitable access to vaccines, Mark was made a Fellow of the Royal Society of the Arts.

Nationality: Dutch

Position: Professor Clinical Biology, Chair of the department Medical Microbiology

After finishing medical school (1991) and completing his PhD research on HIV treatment (1996) at the University of Amsterdam, Menno specialized in clinical microbiology at the Academic Medical Center (AMC). He worked as consultant microbiologist at Leiden University Medical Center and the AMC (2000-2003) before moving to Ho Chi Minh City, Vietnam, where he set up and headed the Virology laboratories at the Oxford University Clinical Research Unit and Hospital for Tropical Diseases. In 2008, he returned to Amsterdam where he was appointed professor of clinical virology and chair of the Department of Medical Microbiology at the Academic Medical Center. After having chaired both departments at the AMC and VUmc since 2018, he is the chair of the merged Amsterdam UMC Department of Medical Microbiology & Infection Prevention since 2020.

As head of the Department, Menno de Jong’s interest in clinical microbiology and infectious diseases is broad and inclusive. However, inspired by his previous work on avian influenza in southeast Asia, his specific research interests remain focused on understanding the pathogenesis and improving treatment of influenza and emerging respiratory viruses, such as SARS-CoV-2. To this extent, his research activities include observational and interventional clinical studies in an international context, complemented by patient-oriented translational research embedded in these studies.  

Passion for people, virology and music! I am a people person who thrives from making connections between diverse, enthusiastic people to enable progress in the communities where I live and work. 

Then comes my passion for learning, understanding and teaching others about viruses, mainly about influenza. About the fascinating ability of Influenza viruses to escape the immunity or become unpredictable. My work has taken me from Anatolia to the United States and now to France and hundreds of places in between, all in an effort to do my part in improving public health by bringing my expertise in vaccine development and sharing my knowledge about influenza with all relevant stakeholders to increase disease awareness and prevention. 

And finally, music which is my refuge from busy everyday life, and which I believe has the magic power that connects people, and repairs souls. I sing when I need to find my way to my soul, and when I feel home-sick I play my baglama, an Anatolian folk music string instrument.

Merel Hellemons is a pulmonologist at Erasmus MC, with a focus on lung transplantation. Together with her colleagues from the lung transplant team, she assesses and guides patients before and after a lung transplant. Hellemons has a special interest in (severe) interstitial lung disease, for which lung transplantation can sometimes be the last remaining treatment.

Furthermore, she is involved in post-COVID care, conducting scientific research and innovation on lung transplantation and recovery after COVID-19.

Nationality: United States

Position: Chief, Respiratory Diseases Branch, Division of Microbiology and Infectious Diseases, NIAID/NIH

Research Fields: Antiviral therapy for RVI, Vaccination in Immunocompromised Hosts

Short description: 

Dr. Michael Ison completed his medical school training at University of South Florida College of Medicine and obtained training in Internal Medicine at Oregon Health Sciences University in Portland, Oregon followed by Infectious Diseases at the University of Virginia.  After spending 17 years as a Professor in the Divisions of Infectious Diseases and Organ Transplantation at Northwestern University Feinberg School of Medicine, he moved to become the Respiratory Disease Branch Chief within the Division of Microbiology and Infectious Diseases at NIAID/NIH.

During his fellowship, he was mentored by Drs. Frederick Hayden, Larisa Gubareva, and Tom Brachiale.  His research focused on the immunopathogenesis of influenza and its treatment in immunosuppressed and hospitalized patients.   He is currently also the Chair of the Antiviral Group of the International Society of Influenza and Other Respiratory Viruses.  He has led a number of clinical studies focused on influenza, RSV and COVID-19 antivirals and vaccines at Northwestern University Feinberg School of Medicine, including the development of a serial sampling biobank, a convalescent plasma bank and a clinical datamart. 

Monika Redlberger-Fritz is a virologist at the Center for Virology at the Medical University of Vienna (Austria), specialised in influenza virus evolution, vaccine effectiveness, and current influenza vaccine research. 

Her areas of responsibility are: Head of the National Reference Laboratory for the Detection and Surveillance of Human Influenza Virus Infections in Austria; Head of the National Reference Laboratory for Respiratory Syncytial Viruses Austria; Head of the Surveillance Network for Respiratory Viruses in Austria; and member of the National Vaccination Committee.

Nabil Jamshed, MSc MBA BBA

Guy's and St Thomas' NHS Foundation Trust, United Kingdom

Mr Nabil Jamshed works as a Head of Corporate Governance for Integrated Specialist Medicine Clinical Group and Chief of Staff at Guy’s and St. Thomas’ NHS Foundation Trust.

He has over 20 years of experience working in the NHS and, internationally, with the Ministry of Public Health and other health agencies in Qatar.

He has operating experience in working with a variety of boards in facilitating the development of effective governance structures and successful board dynamics. He has first-hand experience in introducing constructive governance and risk management models, developing national policy and strategy, working with several Integrated Care Systems (ICS) and understanding and experience in dealing with complex IT systems.

In addition to working with the NHS and health organisations, Nabil had worked in other sectors such as the English Cricket Board and charities, helping with governance and risk management developments and improvements.

As the elected member of the European Health Management Association (EHMA) Scientific Planning Committee, Nabil contributes to wider European healthcare management developments. He has a personal interest in the inclusion agenda and has led various developments within the NHS to support the Equality Diversity and Inclusion efforts and served as a co-chair of the NHS staff BAME network.

Last year, Nabil was appointed as a Non-executive Director at the Black Country Healthcare NHS Foundation Trust. He contributes to the national development and debate on the Equality Diversity and Inclusion through his active membership with the Seacole group of NHS NED and contributions to the APNA (Asian Professionals’ National Alliance) NHS which is a South Asian Heritage NHS Staff Leaders’ network across health and social care.